<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">23124462</PMID>
      <DateCompleted>
        <Year>2013</Year>
        <Month>02</Month>
        <Day>22</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2013</Year>
        <Month>11</Month>
        <Day>21</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1600-5759</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>68</Volume>
            <Issue>Pt 11</Issue>
            <PubDate>
              <Year>2012</Year>
              <Month>Nov</Month>
            </PubDate>
          </JournalIssue>
          <Title>Acta crystallographica. Section C, Crystal structure communications</Title>
          <ISOAbbreviation>Acta Crystallogr C</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Felodipine-diazabicyclo[2.2.2]octane-water (1/1/1).</ArticleTitle>
        <Pagination>
          <StartPage>o456</StartPage>
          <EndPage>o458</EndPage>
          <MedlinePgn>o456-8</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1107/S0108270112043405</ELocationID>
        <Abstract>
          <AbstractText>The title compound, C(18)H(19)Cl(2)NO(4)·C(6)H(12)N(2)·H(2)O, is a cocrystal hydrate containing the active pharmaceutical ingredient felodipine and diazabicyclo[2.2.2]octane (DABCO). The DABCO and water molecules are linked through O-H···N hydrogen bonds into chains around 2(1) screw axes, while the felodipine molecules form N-H···O hydrogen bonds to the water molecules. The felodipine molecules adopt centrosymmetric back-to-back arrangements that are similar to those present in all of its four reported polymorphs. The dichlorophenyl rings also form π-stacking interactions. The inclusion of water molecules in the cocrystal, rather than formation of N-H···N hydrogen bonds between felodipine and DABCO, may be associated with steric hindrance that would arise between DABCO and the methyl groups of felodipine if they were directly involved in hydrogen bonding.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Solanko</LastName>
            <ForeName>Katarzyna A</ForeName>
            <Initials>KA</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Physics, Chemistry and Pharmacy, University of Southern Denmark, Campusvej 55, 5230 Odense, Denmark.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Surov</LastName>
            <ForeName>Artem O</ForeName>
            <Initials>AO</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Perlovich</LastName>
            <ForeName>German L</ForeName>
            <Initials>GL</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bauer-Brandl</LastName>
            <ForeName>Annette</ForeName>
            <Initials>A</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bond</LastName>
            <ForeName>Andrew D</ForeName>
            <Initials>AD</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2012</Year>
          <Month>10</Month>
          <Day>31</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Acta Crystallogr C</MedlineTA>
        <NlmUniqueID>8305826</NlmUniqueID>
        <ISSNLinking>0108-2701</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D001372">Aza Compounds</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D034242">Cyclooctanes</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C578397">diazabicyclo(2.2.2)octane</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>OL961R6O2C</RegistryNumber>
          <NameOfSubstance UI="D015736">Felodipine</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D001372" MajorTopicYN="N">Aza Compounds</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018360" MajorTopicYN="N">Crystallography, X-Ray</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D034242" MajorTopicYN="N">Cyclooctanes</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015736" MajorTopicYN="N">Felodipine</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006860" MajorTopicYN="N">Hydrogen Bonding</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008958" MajorTopicYN="N">Models, Molecular</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015394" MajorTopicYN="N">Molecular Structure</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2012</Year>
          <Month>10</Month>
          <Day>5</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2012</Year>
          <Month>10</Month>
          <Day>18</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2012</Year>
          <Month>11</Month>
          <Day>6</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2012</Year>
          <Month>11</Month>
          <Day>6</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2013</Year>
          <Month>2</Month>
          <Day>23</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">23124462</ArticleId>
        <ArticleId IdType="doi">10.1107/S0108270112043405</ArticleId>
        <ArticleId IdType="pii">S0108270112043405</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
